• Follow us
  • Holding BUMN Farmasi
  • For Healthcare Professional
  • Researcher
  • EN
    Flag IndonesiaID
    Flag EnglishEN
biofarma-logo-bumn biofarma-logo biofarma-logo-131 biofarma-logo-hashtag-only-case
  • Home
  • Who We Are

    About Us
    • Our Focus
    • Our Strategy
    • Our Distribution
    • Our Operations
    • Your Career
    Our Leadership
    • Corporate Executive Team
    • Management Team
    Our Achievement
    • Awards
    • Certification
    Sustainability
    • Our People
    • Access to Vaccine
    • Corporate Social Responsibility
    • Good Corporate Governance
    • Biodiversity
  • Product & Service

    Our Product
    • Combination Vaccine
    • Viral Vaccine
    • Bacterial Vaccine
    • Diagnostic Vaccine
    • Sera
    Our Health Service
    • Service of Industrial Micro Biology
    • Clinical Laboratory Service
    • Vaccination Service
    • Clinic & Pharmacy

    Visit our website

  • Media

    For Media
    • Latest News
    • Current Event
    Vaccine Fact
    Media Release
    FAQ
  • I Want to
search

50th Delivery of Covid-19 Vaccine Arrives at Bio Farma: Covid-19 Vaccine Supply is Safe Covid-19 Vaccine Distribution Continues

Tuesday, 7 September 2021

 

 

Bio Farma vaccine storage officer, transferred five million doses of CoronaVac 2 ds vaccine to a special storage facility, with a temperature of 2-8 degrees Celsius at Bio Farma (6/9). The vaccine received from Sinovac in the form of a finish product, is the 50th shipment, then it will wait for the process of giving and taking samples from the POM, before being distributed to 34 provinces according to the directives from the Ministry of Health, (Photo: Andzar | Corcom Bio Farma).

 

(Bandung 7/9) Bio Farma received CoronaVac 2 dose vaccine from Sinovac, in the finished product for the sixth time , as many as five million doses. The delivery of CoronaVac 2 doses is a continuation of the delivery of a total of 50 million doses, which will be received by Bio Farma, in the period August - September 2021.The arrival of the CoronaVac 2ds vaccine is the 50th arrival since 10 months ago in December 2020. This 50th arrival is a clear proof of the seriousness of the Indonesian government in ensuring the availability of vaccine stocks to meet the needs of the Covid-19 vaccine in Indonesia. Indonesia. This was conveyed by the Coordinating Minister for Economic Affairs of the Republic of Indonesia, Airlangga Hartarto in a virtual press statement upon the arrival of the CoronaVac vaccine on (6/9) at 13:00.

"The vaccine in the finished form from CoronaVac, has received 33 million doses, (the first three million, received in December 2020 which were used for health workers), while the Sinovac vaccine in bulk form was received as many as 153.9 million, AstraZeneca as much as 19.5 million doses, Moderna eight million doses, Pfizer 2.75 million doses, Sinopharm 8.25 million doses,” said Airlangga.

He added, in total, Indonesia has secured a total of 225.4 million doses of Covid-19 vaccines from various brands, both in bulk form and in the form of finished products. With the arrival of the 2-dose CoronaVac vaccine today (6/9), it is certain that the supply of Covid-19 vaccine is safe. 

Airlangga emphasized that people should not hesitate to receive vaccines, because all vaccine brands are efficacious to protect the community, and the best vaccine is the vaccine currently available.

On another occasion, the Corporate Secretary and Spokesperson for Bio Farma, Bambang Heriyanto said, the 2-dose CoronaVac vaccine received today at Soekarno-Hatta Airport, will soon pass the quarantine and sampling process before getting a lot release from the POM Agency for distribution to other countries. 34 provinces in Indonesia.

"From the supply of Covid-19 vaccines which has reached 225.4 million doses, Bio Farma has distributed Covid-19 vaccines since January - until the first week of September as many as 141.4 million doses, consisting of; CoronaVac 1 dose, three million doses, Bio Farma Covid-19 93.06 million doses, AstraZeneca (Covax, B2B and Grants) 16.8 million doses, Moderna 7.6 million doses, CoronaVac 2 20.4 million doses and Sinopharm (grant) of 499.9 thousand doses,” said Bambang.

The remaining stock at Bio Farma itself as of September 5, 2021 is 14.9 million doses, which will be distributed immediately after receiving a request from the Indonesian Ministry of Health. It is estimated that in September 2021, Indonesia will receive an additional 16.5 million vaccine stocks for Bio Farma's Covid-19 vaccine, which will be processed by fill and finish at Bio Farma's production facilities. 

In September 2021, Indonesia will receive additional 2 doses of CoronaVac vaccine in the form of a finish product of 25 million doses of vaccine, as well as additional vaccines from the Covax/Gavi multilateral scheme, bilateral and other bilateral donations, so that the total availability of vaccine stocks in Indonesia is estimated. Indonesia's supply in September is expected to reach more than 70 million doses. (ed)

  • Share to:
Download

Latest News

DSC03514
Thursday, 9 June 2022
Phase 3 Clinical Trial of Bio Farma's Covid-19 Vaccine Commencing Soon, Indonesia Will Be Independent in Making Covid-19 Vaccine
PIALA BMGF
Thursday, 19 May 2022
Bio Farma Receives Appreciation from the Bill and Melinda Gates Foundation
BIO FARMA MDI
Wednesday, 11 May 2022
Building Bio-Health Fund, Bio Farma Together with MDI Invest to Targeting Opportunities in Health Sector Startups
View more

Head Office
Jl. Pasteur No. 28, Bandung 40161,
Jawa Barat Indonesia
No. Telp
+62 22-2033755
Fax
+62 22 - 2041306
Bio Care
1500810
Email
mail@biofarma.co.id
website
www.biofarma.co.id
Digital Healthcare Office Jakarta Lt. 26
Equity Tower Sudirman Central Business District (SCBD) Lot 9
Jl. Jend. Sudirman Kav. 52-53
Jakarta Selatan 12190, Indonesia
Information
  • Good Corporate Governance
  • Our Procurement
  • FAQ
  • Vaccine Production
  • Your Career
 
  • Contact Us
  • E-PPID
  • Announcement
  • I Want to
  • Media Release
Our Partner

Quick Links
  • Portal BUMN-Bio
  • Kemenkes RI
Copyright © 2022. All Rights Reserved by Bio Farma
Holding BUMN Farmasi
For Healthcare Professional
Researcher

Change Language

EN
  • Home
  • Who We Are
    • About Us
      • About Us
      • Our Focus
      • Our Strategy
      • Our Distribution
      • Our Operations
      • Your Career
    • Our Leadership
      • Corporate Executive Team
      • Management Team
    • Our Achievement
      • Awards
      • Certification
    • Sustainability
      • Our People
      • Access to Vaccine
      • Corporate Social Responsibility
      • Good Corporate Governance
      • Biodiversity
  • Product & Service
    • Our Product
      • Our Product
      • Combination Vaccine
      • Viral Vaccine
      • Bacterial Vaccine
      • Diagnostic Vaccine
      • Sera
    • Our Health Service
      • Our Health Service
      • Service of Industrial Micro Biology
      • Clinical Laboratory Service
      • Vaccination Service
      • Clinic & Pharmacy
  • Media
    • For Media
      • For Media
      • Latest News
      • Current Event
    • Vaccine Fact
    • Media Release
    • FAQ
  • I Want to
  • Follow us
Change Language
  • Flag IndonesiaID
  • Flag EnglishEN
BIO CARE 1500810 icon-phone
Youtube icon-youtube
Corporate Reporting icon-statistics